Marijuana / THC

Frequency of use is the single largest determinant of how long THC remains detectable. Someone who smokes a single joint at a party is generally negative within three to seven days on a standard 50 ng/mL immunoassay. A daily user who has been consuming for months may continue to test positive for four to six weeks after the last use, and in well-documented chronic-user studies a small subset of subjects produced positive results for more than 70 days of abstinence. The accumulation effect is not linear — it builds with cumulative exposure and is released as fat stores are mobilized.

Body composition matters because THC-COOH is stored in adipose tissue. Individuals with a higher percentage of body fat have a larger reservoir to release back into circulation over time. Weight loss, particularly rapid weight loss following a period of regular use, can transiently elevate urinary THC-COOH as fat cells release stored metabolite. This is one reason laboratories that confirm positive results with mass spectrometry can sometimes detect THC-COOH long after a donor reports being abstinent.

Metabolic rate, hepatic enzyme activity, and overall health influence how quickly the liver converts THC to its metabolites and how quickly those metabolites are excreted. Hydration affects the concentration of metabolites in any given urine sample — a heavily diluted specimen will show lower THC-COOH levels and, if creatinine drops below 20 mg/dL or specific gravity below 1.003, federal programs may flag the sample as dilute and order recollection. Dilution does not eliminate the metabolite; it simply lowers its concentration, often below the screening cutoff.

Route of administration changes the pharmacokinetic profile substantially. Inhaled THC reaches peak blood levels within minutes and is largely cleared from blood within hours, although metabolites persist much longer. Oral THC, including edibles and pharmaceutical dronabinol, undergoes first-pass hepatic metabolism that produces a higher proportion of 11-hydroxy-THC, an active metabolite that itself is psychoactive. Edible users sometimes report longer-lasting effects and may also show different metabolite ratios on confirmation testing. Age, comorbidities, and concurrent medications all play smaller modifying roles in individual cases.

SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs establish the cutoff levels that federally regulated employers — DOT, federal civilian agencies, and federal contractors covered by the Drug-Free Workplace Act — must use. For marijuana, the initial immunoassay screening cutoff is 50 ng/mL of THC-COOH in urine. Specimens that test at or above this level proceed to confirmation testing by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS), where the confirmatory cutoff for THC-COOH is 15 ng/mL.

Non-federal employers and clinical programs are free to set their own cutoffs, and many do. A 20 ng/mL screening cutoff is common in pain-management and substance-use-disorder treatment settings where clinicians want greater sensitivity to recent use. Some forensic programs use 10 ng/mL or even lower. Magenta's CLIA-waived dip cards and cups are calibrated to the SAMHSA 50 ng/mL THC cutoff by default; talk to us about custom cutoffs for clinical or specialty applications.

Saliva and hair testing use different cutoffs. SAMHSA's oral-fluid guidelines specify a 4 ng/mL initial cutoff for THC parent compound and a 2 ng/mL confirmation cutoff. Hair testing is not yet a SAMHSA-authorized matrix for federal programs as of this writing; commercial laboratories typically use 1 pg/mg for THC-COOH on hair, with the explicit understanding that hair results cannot establish a time of use within the 90-day window represented by the sample.

Lateral-flow immunoassay is the workhorse of point-of-care THC screening. The test strip contains a membrane impregnated with anti-THC-COOH antibodies and a colored conjugate. When urine wicks up the strip, free THC-COOH from the sample competes with the labeled conjugate for antibody binding sites. If THC-COOH is present at or above the cutoff, it occupies enough antibody binding sites that the conjugate cannot accumulate at the test line, producing a negative-line, positive-result pattern. The control line confirms reagents are working. All Magenta dip cards and cups use this format.

Immunoassay screens are designed to be sensitive and conservative. They detect THC-COOH but also exhibit some degree of cross-reactivity with other cannabinoids and structurally similar compounds. Cross-reactivity is generally documented in the test's package insert. False positives from common over-the-counter medications are rare for THC tests, in contrast to amphetamine assays which have well-known cross-reactivity issues. Where cross-reactivity does matter for marijuana is in the context of CBD products: legal hemp-derived CBD products are required to contain less than 0.3% THC by dry weight, but routine consumption of a full-spectrum CBD product can produce enough cumulative THC exposure to trigger a positive screen, particularly in heavy daily users of CBD.

Confirmation testing by GC/MS or LC-MS/MS is the gold standard for resolving any presumptive positive. These instrumental methods identify THC-COOH by its specific mass spectrum and quantify it precisely, distinguishing the metabolite from any cross-reacting cannabinoid. SAMHSA-certified laboratories perform confirmation testing on every screening positive, and a Medical Review Officer (MRO) reviews confirmed positives to identify legitimate medical explanations — though, as noted above, state-level medical marijuana authorization does not provide a defense for federally regulated employees.

Specimen validity testing accompanies every workplace screen. Laboratories and point-of-care devices check creatinine and specific gravity to identify dilute specimens, pH to identify adulteration with household chemicals, and oxidizing-agent panels to identify products marketed to defeat drug tests. Magenta's adulteration-panel cups include creatinine, pH, specific gravity, glutaraldehyde, nitrite, and oxidant test pads. A positive adulteration panel finding generally triggers a refusal-to-test consequence under federal rules, equivalent to a confirmed positive.

Newer testing modalities continue to evolve. Oral-fluid testing is growing in workplace adoption because it correlates better with recent use and impairment, important in safety-sensitive industries where employers care about whether a worker is currently impaired rather than whether they consumed marijuana over a weekend. Breath-based THC testing is in late-stage development but is not yet a SAMHSA-authorized matrix. Programs evaluating any new matrix should verify FDA clearance status and SAMHSA recognition before relying on results for adverse employment action.